Ruxolitinib Metformin combo: A Possible Alternative Treatment for Myeloproliferative Neoplasm Patients

How MPN Blood Cancers outsmart the Immune System
February 22, 2018
MPN research
ASH Partners with UNC, a ClinGen grantee to Curate Genomic data for Blood Research
April 9, 2018

Ruxolitinib Metformin combo: A Possible Alternative Treatment for Myeloproliferative Neoplasm Patients

MPN cells

Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & Disease.

The JAK1/2 inhibitor ruxolitinib demonstrates clinical activity among patients with MPN (eg, essential thrombocythemia, primary myelofibrosis, polycythemia vera), but rarely produces a complete response. Data from previous studies have shown that metformin may selectively inhibit hematologic malignant cells.

For this study, researchers assessed the activity of metformin and ruxolitinib alone or in combination in various human lines, including the JAK2V617F-positive cell lines HEL and SET2.

Assay results showed that metformin alone reduced cell viability in a dose- and time-dependent manner, and further analysis of metformin and ruxolitinib alone confirmed significantly reduced cell viability.
Click here for the complete article – courtesy of Oncology Nurse Advisor

Comments are closed.

Do NOT follow this link or you will be banned from the site!
Malcare WordPress Security